AMA
Bik-MultanowskI M, Jamroz E, Kaluzny L, et al. Long-term clinical effects of enzyme replacement
therapy in MPS II. Pediatria Polska - Polish Journal of Paediatrics. 2017;92(4):373-377.
APA
Bik-MultanowskI, M., Jamroz, E., Kaluzny, L., Pronicka, E., Rokicki, D., & Starostecka, E. et al. (2017). Long-term clinical effects of enzyme replacement
therapy in MPS II. Pediatria Polska - Polish Journal of Paediatrics, 92(4), 373-377.
Chicago
Bik-MultanowskI, Miroslaw, Ewa Jamroz, Lukasz Kaluzny, Ewa Pronicka, Dariusz Rokicki, Ewa Starostecka, and Jolanta Sykut-Cegielska et al. 2017. "Long-term clinical effects of enzyme replacement
therapy in MPS II". Pediatria Polska - Polish Journal of Paediatrics 92 (4): 373-377.
Harvard
Bik-MultanowskI, M., Jamroz, E., Kaluzny, L., Pronicka, E., Rokicki, D., Starostecka, E., Sykut-Cegielska, J., Wierzba, J., and Walczak, M. (2017). Long-term clinical effects of enzyme replacement
therapy in MPS II. Pediatria Polska - Polish Journal of Paediatrics, 92(4), pp.373-377.
MLA
Bik-MultanowskI, Miroslaw et al. "Long-term clinical effects of enzyme replacement
therapy in MPS II." Pediatria Polska - Polish Journal of Paediatrics, vol. 92, no. 4, 2017, pp. 373-377.
Vancouver
Bik-MultanowskI M, Jamroz E, Kaluzny L, Pronicka E, Rokicki D, Starostecka E et al. Long-term clinical effects of enzyme replacement
therapy in MPS II. Pediatria Polska - Polish Journal of Paediatrics. 2017;92(4):373-377.
